Abstract
Purpose :
To assess safety and efficacy of the Hydrus microstent (Ivantis, Inc, Irvine, CA) with combined phacoemulsification in patients with open angle glaucoma (OAG).
Methods :
This retrospective study evaluates the data of 38 eyes of 34 patients with open angle glaucoma scheduled for a Schlemm’s canal
microstent (Hydrus) with a combined phacoemulsification. Postoperative IOP and topical anti glaucomatous therapy were obtained at 1 day, 4 weeks, 3, 6, and 12 months. In addition, intra and postoperative complication were documented during the study period of 12 months.
Results :
After implantation mean IOP decreased statistically significant throughout the follow up (preoperative: 17.42 mmHg ±4.14 SD, after 12 months 15.17 mmHg ±2.18 SD, p=0.018). Medication reduced from mean 2.67 ±1.35 (range 0 to 5) preoperatively to mean 0.89 ±1.13 range 0 to 3) after 12 months (p=0.001). In 2 patients implantation was not possible and they were excluded from the follow up. No device related adverse event occurred. Transient IOP elevation >21 mmHg was present in 8 patients. One patient had a significant hyphema and a single fibrinous anterior chamber reaction occurred.
Conclusions :
The Hydrus microstent with combined phacoemulsification is a safe and effective tool in lowering IOP and reducing anti-glaucoma medication.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.